Genex Pharmaceutical, Inc.
GENX · OTC
12/31/2007 | 12/31/2006 | 12/31/2005 | 12/31/2004 | |
|---|---|---|---|---|
| Revenue | $3,237 | $2,438 | $2,491 | $2,350 |
| % Growth | 32.8% | -2.1% | 6% | – |
| Cost of Goods Sold | $363 | $217 | $302 | $283 |
| Gross Profit | $2,874 | $2,221 | $2,189 | $2,067 |
| % Margin | 88.8% | 91.1% | 87.9% | 88% |
| R&D Expenses | $196 | $1 | $86 | $0 |
| G&A Expenses | $1,180 | $699 | $0 | $0 |
| SG&A Expenses | $2,212 | $1,373 | $1,182 | $1,075 |
| Sales & Mktg Exp. | $1,032 | $674 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,408 | $1,374 | $1,268 | $1,075 |
| Operating Income | $466 | $847 | $921 | $992 |
| % Margin | 14.4% | 34.7% | 37% | 42.2% |
| Other Income/Exp. Net | $267 | $179 | $33 | $21 |
| Pre-Tax Income | $734 | $1,026 | $953 | $1,013 |
| Tax Expense | $391 | $407 | $328 | $0 |
| Net Income | $343 | $619 | $625 | $1,013 |
| % Margin | 10.6% | 25.4% | 25.1% | 43.1% |
| EPS | 0.019 | 0.03 | 0.04 | 0.06 |
| % Growth | -36% | -25% | -33.3% | – |
| EPS Diluted | 0.019 | 0.03 | 0.04 | 0.06 |
| Weighted Avg Shares Out | 17,846 | 17,846 | 17,846 | 17,846 |
| Weighted Avg Shares Out Dil | 17,846 | 17,846 | 17,846 | 17,846 |
| Supplemental Information | – | – | – | – |
| Interest Income | $254 | $179 | $69 | $23 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $56 | $55 | $60 | $59 |
| EBITDA | $790 | $903 | $980 | $1,051 |
| % Margin | 24.4% | 37% | 39.4% | 44.7% |